Literature DB >> 18686048

Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients.

Nuray Buyukberber1, Süleyman Buyukberber, Alper Sevinc, Celalettin Camci.   

Abstract

Assay of cytokines and C reactive protein (CRP) in different periods of febrile neutropenia may be helpful for early defining the risk in severe infections. We determined serum interleukin-6 (IL-6), interleukin-8 (IL-8), soluble interleukin-2 receptor (sIL-2R), tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and CRP in 22 previously untreated patients with various malignancies. Samples were obtained in four different clinical periods of febrile neutropenia; prior to chemotherapy, afebrile neutropenic period after chemotherapy, febrile neutropenic period, and recovery period. When compared to sex-and age-matched group of healthy subjects, IL-6, IL-8, sIL-2R, and CRP levels were found to be elevated in all periods. The highest levels were encountered in the febrile neutropenic period. For predictivity purposes, the afebrile neutropenic period was the most important period. Serum sIL-2R, IL-6, IL-8 and CRP levels were elevated in this period. IL-8 levels showed the most stable elevation through different stages of febrile neutropenia. Serum IL-8 levels were found to have the most reliable and stable elevation in different clinical stages of febrile neutropenia. Nevertheless, IL-8 is not able to discriminate among risk groups and cannot be used as a predictive factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18686048     DOI: 10.1007/s12032-008-9081-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  38 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia.

Authors:  Lennart Persson; Bo Söderquist; Per Engervall; Tomas Vikerfors; Lars-Olof Hansson; Ulf Tidefelt
Journal:  Eur J Haematol       Date:  2005-04       Impact factor: 2.997

3.  Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children.

Authors:  Glenn R Stryjewski; Eric S Nylen; Michael J Bell; Richard H Snider; Kenneth L Becker; Amy Wu; Christopher Lawlor; Heidi Dalton
Journal:  Pediatr Crit Care Med       Date:  2005-03       Impact factor: 3.624

Review 4.  Risk assessment and treatment of low-risk patients with febrile neutropenia.

Authors:  Winfried V Kern
Journal:  Clin Infect Dis       Date:  2006-01-06       Impact factor: 9.079

5.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

6.  Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule.

Authors:  J A Talcott; A Whalen; J Clark; P P Rieker; R Finberg
Journal:  J Clin Oncol       Date:  1994-01       Impact factor: 44.544

7.  A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia.

Authors:  F A Manian
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079

8.  Kinetics and correlation with body temperature of circulating interleukin-6, interleukin-8, tumor necrosis factor alpha and interleukin-1 beta in patients with fever and neutropenia.

Authors:  A Engel; W V Kern; G Mürdter; P Kern
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

9.  Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia.

Authors:  P Engervall; B Andersson; M Björkholm
Journal:  Br J Haematol       Date:  1995-12       Impact factor: 6.998

10.  Interleukin 8 in serum in granulocytopenic patients with infections.

Authors:  A Waage; D Remick; S Steinshamn; L Deforge; J Lamvik
Journal:  Br J Haematol       Date:  1994-01       Impact factor: 6.998

View more
  10 in total

1.  Biomarker candidates for the detection of an infectious etiology of febrile neutropenia.

Authors:  Martin E Richter; Sophie Neugebauer; Falco Engelmann; Stefan Hagel; Katrin Ludewig; Paul La Rosée; Herbert G Sayer; Andreas Hochhaus; Marie von Lilienfeld-Toal; Tom Bretschneider; Christine Pausch; Christoph Engel; Frank M Brunkhorst; Michael Kiehntopf
Journal:  Infection       Date:  2015-08-15       Impact factor: 3.553

Review 2.  Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor.

Authors:  Susannah K Leaver; Niall S MacCallum; Vasisht Pingle; Matthew B Hacking; Gregory J Quinlan; Timothy W Evans; Anne Burke-Gaffney
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

3.  Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients.

Authors:  Letícia Carvalho Neuenschwander; Henrique Bittencourt; Ana Flávia Tibúrcio Ribeiro; Antônio Lúcio Teixeira; Mauro M Teixeira; Jairo Cerqueira Teixeira; Vandack Nobre
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia.

Authors:  Pedro Póvoa; Vicente Ces Souza-Dantas; Márcio Soares; JorgeI F Salluh
Journal:  Crit Care       Date:  2011-05-19       Impact factor: 9.097

5.  Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation.

Authors:  Michaela Döring; Karin Melanie Cabanillas Stanchi; Markus Mezger; Annika Erbacher; Judith Feucht; Matthias Pfeiffer; Peter Lang; Rupert Handgretinger; Ingo Müller
Journal:  BMC Cancer       Date:  2015-08-28       Impact factor: 4.430

6.  Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy.

Authors:  Hiromi Nishi; Kouji Ohta; Yuri Kuramoto; Hideo Shigeishi; Taiji Obayashi; Yukio Yoshioka; Masaru Konishi; Shuichi Munenaga; Hisao Nagoshi; Tetsumi Yoshida; Noriyasu Fukushima; Naoya Kakimoto; Hiroki Ohge; Hidemi Kurihara; Tatsuo Ichinohe; Hiroyuki Kawaguchi
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.996

7.  Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia.

Authors:  A F Tibúrcio Ribeiro; V Nobre; L C Neuenschwander; A L Teixeira; S G Xavier; F D F Paula; M M Teixeira; J C A Teixeira; H Bittencourt
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

8.  Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study.

Authors:  Steven M Chan; John Chadwick; Daniel L Young; Elizabeth Holmes; Jason Gotlib
Journal:  Hematol Rep       Date:  2014-06-23

Review 9.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

10.  Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy.

Authors:  Mira Siegmund; Julia Pagel; Tasja Scholz; Jan Rupp; Christoph Härtel; Melchior Lauten
Journal:  Mol Cell Pediatr       Date:  2020-06-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.